Chronic comorbidity of internal organs as a risk factor of complications and fatal outcome of community-acquired pneumonia.

Y. M. Mostovoy, A. V. Demchuk, T. V. Konstantynovych, K. D. Chichirelo-Konstantynovych

Abstract


With the purpose to estimate influence of comorbidity at the risk of complications and death due to community-acquired pneumonia (CAP) the retrospective analysis of 1587 case histories of inpatients with CAP (mean age – 48.5±18.4, males – 815 (51.4%), women – 772 (48,6%)) was performed. Comorbidity was observed in 1114 (70.2%). More frequently complications of CAP were developed in patients with chronic diseases than without them (p=0.013). Increased risk of pleural effusion was associated with chronic diseases of digestive system (OR=1.85 (95%CI 1.30-2.26)) and diabetes mellitus (OR=2.35 (95%CI 1.40-3.96)). Risk of sepsis development is higher in patients with nervous system diseases (OR=3.62 (95%CI 1.37-9.56) and drug or alcohol addiction (OR=19.08 (95%CI 7.30-49.82). Risk of pulmonary edema rose in patients with drug or alcohol addiction (OR=24.16; 95%CI 8.07-72.34), malignancy (OR=8.97; 95%CI 1.94-41.49), diabetes mellitus (OR=4.04; 95%CI 1.48-11.01), diseases of nervous (OR=4.04; 95%CI 1.17-13.94), urinary (OR=3.39; 95%CI 1.33-8.64) and cardiovascular (OR=2.29, 95%CI 0.98-5.34) systems. Higher risk of death in patients with CAP was associated with the presence of cardiovascular diseases (OR=2.17; 95%CI 1.11-4.25), diabetes mellitus (OR=2.95; 95%CI 1.20-7.21), drug or alcohol addiction (OR=38.40; 95%CI 15.05-97.98).

 


Keywords


community-acquired pneumonia; chronic diseases of internal organs

References


Ivanovskiy VB,PaukerMN,NeyshtandtAS.[Sta­ges and quality of medical diagnosis of long-term pneumonia in a tuberculosis hospital]. Klinicheskaya Medicina 2011;1:31-34. Russian.

Ishiguro T, Takayanagi N, Yamaguchi S, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med. 2013;52:317-24.

Sellares J, Lopez-Giraldo A. Lucena C, et al. In­fluence of previous use of inhaled corticoids on the de­velopment of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med. 2013;187(11):1241-8.

Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013;41:974984.

Ruhnke GW, Coca-Perraillon M, Kitch BT, et al. Marked improvement in 30-day mortality among elderly inpatients and outpatients with community-acquired pneu­monia. Am J Med. 2011;124:171-8.

Almirall J, Bolibar I, Serra-Prat M, et al. New evi­dence of risk factors for community-acquired pneu­monia: a population-based study. Eur Respir J. 2008;31:1274-84.

Martin-Loeches I, Valles X, Menendez R, et al. Pre­dicting treatment failure in patients with community-acquired pneumonia: a case-control study. Respir Res 2014;15(1):75.

Sibila O, Mortensen EM, Anzueto A, et al. Prior car­diovascular disease increases long-term mortality in COPD patients with pneumonia. Eur Respir J 2014;43:36-42.

Sicras-Mainar A, Ibanez-Nolla J, Cifuentes I, et al. Retrospective epidemiological study for the charac­terization of community-acquired pneumonia and pneu­mococcal pneumonia in adults in a well-defined area of Ba­dalona (Barcelona, Spain). BMC Infect Dis 2012;12:283. Available from: http://www.biomedcentral.com/1471-2334/­12/283

Dusemuna F, Chronis J, Baty F, et al. The out­come of community-acquired pneumonia in patients with chronic lung disease. Swiss Med Wkly 2014;144:w14013. Available from: www.smw.ch

Torres A, Blasi F, Dartois N, et al. Which in­dividuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015;70:984-9.


GOST Style Citations


  1. Ивановский В.Б. Этапы и качество лечебной диагностики пневмоний затяжного течения в ту­беркулезном стационаре // В. Б. Ивановский, М.Н. Па­укер, А.С. Нейштандт // Клинич. медицина. – 2011. – № 1. – C. 31-34.
  2. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia / T. Ishiguro, N. Takayanagi, S. Yamaguchi [et al.] // Inter. Med. – 2013. – Vol. 52. – P. 317-324.
  3. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia / J. Sellares, A. Lopez-Giraldo, C. Lucena [et al.] // Am. J. Resp. Crit. Care Med. – 2013. – Vol. 187, N 11. – P. 1241-1248.
  4. Kolditz M. Management-based risk prediction in community-acquired pneumonia by scores and biomar­kers / M. Kolditz,S. Ewig, G. Hoffken // Eur. Resp. J. – 2013. – Vol. 41. – P. 974-984.
  5. Marked improvement in 30-day mortality among elderly inpatients and outpatients with community-acquired pneumonia / G.W. Ruhnke, M. Coca-Perraillon, B. T. Kitch [et al.] // Am. J. Med. – 2011. – Vol. 124. – Р. 171-178.
  6. New evidence of risk factors for community-acquired pneumonia: a population-based study / J. Almi­rall, I. Bolibar, M. Serra-Prat [et al.] // Eur. Respir. J. – 2008. – Vol. 31. – P. 1274-1284.
  7. Predicting treatment failure in patients with community-acquired pneumonia: a case-control study / I. Martin-Loeches, X. Valles, R. Menendez [et al.] // Resp. Res. – 2014. – Vol. 15, N 1. – P. 75.
  8. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia / O. Sibila, E.M. Mortensen, A. Anzueto [et al.] // Eur. Resp. J. – 2014. – Vol. 43. – P. 36-42
  9. Retrospective epidemiological study for the cha­racterization of community-acquired pneumonia and pneu­mococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain) [Електронний ресурс] / A. Sicras-Mainar, J. Ibanez-Nolla, I. Cifuentes [et al.] // BMC Infect. Dis. – 2012. – Vol. 12. – P. 283. Режим доступу: http://www.biomedcentral.com/1471-2334/12/283.
  10. The outcome of community-acquired pneumonia in patients with chronic lung disease [електронний ре­сурс] / F. Dusemuna, J. Chronis, F. Baty [et al.] // Swiss. Med. Wkly. – 2014. – Vol. 144. – w14013. Режим дос­тупу: www.smw.ch.
  11.  Which individuals are at increased risk of pneu­mococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on com­munity-acquired pneumonia and invasive pneumococcal disease / A. Torres, F. Blasi, N. Dartois [et al.] // Thorax. – 2015. – Vol. 70. – P. 984-989.




DOI: https://doi.org/10.26641/2307-0404.2018.1(part1).127248

Refbacks

  • There are currently no refbacks.